Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REEF: Ranibizumab 0.5mg and 2.0mg for Residual DME
NCT01292798Phase 2Completed
- Sponsor
- California Retina Consultants
- Start
- Mar 2011
- Primary completion
- Apr 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in diabetic macular edema (DME), sponsored by California Retina Consultants. Started Mar 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01292798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292798.